Introduction

This year, EGFR+ UK conducted the biggest survey of EGFR+ lung cancer patients in the UK. We are now able to bring you the results of this significant research, which sheds light on the real experiences and challenges faced by our community.

Key Highlights

Delays in Diagnosis:

40% of respondents waited more than 4 weeks to identify their EGFR mutation, with more than 10% waiting over 10 weeks. These delays impact treatment start times and outcomes.

Mental Health and Support:

Over three-quarters (83.3%) of the respondents reported significant "scanxiety" and above-normal levels of anxiety and depression. 32.8% likely have diagnosable anxiety, and 26.6% likely have depression, highlighting the need for better mental health support.

Surveillance and Follow-up:

While most received regular CT scans (87.8%), fewer than half (35.9%) received brain MRIs as routine. Variability in waiting times for scan results was also reported, indicating inconsistencies in follow-up care.

Patient Support Resources:

Despite high levels of mental health issues, 1-in-2 patients didn't have, or didn't know if they had, access to counselling within their hospital. Furthermore, 1-in-5 patients didn't have, or didn't know if they had, a Clinical Nurse Specialist (CNS).

Impact and Next Steps

This survey has provided invaluable insights that will help us advocate for better care and support for EGFR+ lung cancer patients. This data is crucial for driving improvements in the care and resources available to our community.